(MENAFN- EQS Group)
DGAP-News: ABIVAX / Key word(s): AGM/EGM
ABIVAX: Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents
18.05.2022 / 18:00
The issuer is solely responsible for the content of this announcement.
Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents
PARIS, France, May 18, 2022 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, informs its shareholders that its ordinary and extraordinary general meeting will be held on June 9, 2022, at 10:00 a.m. (CEST), at the offices of Dechert (Paris) LLP, located at 32 rue de Monceau in Paris (75008), France.
The Shareholders' Meeting documents and information and the voting form have been made available to Shareholders under the terms and conditions specified by current French regulations, and are available on the Company's website . All documents are exclusively available in French.
*****
About Abivax (
Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at . Follow us on Twitter @ABIVAX_.
Contacts
Abivax
Communications
Regina Jehle
+33 6 24 50 69 63
| Investors
LifeSci Advisors
Ligia Vela-Reid
+44 7413 825310
| Press Relations & Investors Europe
MC Services AG
Anne Hennecke
+49 211 529 252 22
|
Public Relations France
Actifin
Ghislaine Gasparetto
+33 6 21 10 49 24 | Public Relations France
Primatice
Thomas Roborel de Climens
+33 6 78 12 97 95 | Public Relations USA
Rooney Partners LLC
Jeanene Timberlake
+1 646 770 8858 |
18.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at
MENAFN18052022004691010666ID1104236961
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.